Physician profile
Wanda Freeman
NPI 1659504264
$3,298.49
in general payments reported to CMS, 2019-2025
14 companies · $32.08 in 2025
The $32.08 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,614 · 2022: $1,329 · 2023: $323 · 2025: $32.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,595.99 | 2021-2022 | |
| Abbvie INC. | $477.98 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $249.68 | 2021-2023 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $184.85 | 2021-2023 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $172.31 | 2021-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $115.76 | 2021-2023 | Austedo |
| Alkermes, INC. | $103.57 | 2021-2023 | Vivitrol |
| Lundbeck LLC | $101.42 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $86.47 | 2021-2023 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $81.51 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.50 | 2021 | |
| Gilead Sciences, INC. | $32.08 | 2025 | |
| Supernus Pharmaceuticals, INC. | $24.51 | 2023 | Qelbree |
| Corium, LLC | $15.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.